TWSTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Twist Bioscience Corp
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$139.77+7.02 (+5.29%)
Close on Oct 19, 2026
- Market cap
- $8.72B
- P/E (TTM)
- –
- Dividend yield
- –
Twist Bioscience Corp revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Reportable Segment | $376.57M | $312.97M | $245.11M | – | – | – | – | – | – | 100.0% | +20.3% |
| Industry and applied | – | – | – | – | – | $40.04M | $17.42M | $4.21M | $1.23M | – | – |
| Agricultural [Member] | – | – | – | – | – | – | $1.20M | $490.00K | $130.00K | – | – |
| Industrial Chemicals [Member] | – | – | – | – | – | $29.05M | $21.93M | $14.91M | $6.70M | – | – |
| Academic Research [Member] | – | – | – | – | – | $19.64M | $13.84M | $5.81M | $2.71M | – | – |
| Food And Agriculture [Member] | – | – | – | – | – | $1.37M | $1.20M | $490.00K | – | – | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NGS applications | $208.10M | $169.13M | $123.71M | $99.31M | $72.67M | $44.02M | $21.04M | $2.67M | $72.00K | 55.3% | +23.0% |
| Synthetic genes | $113.60M | $92.68M | $73.54M | $61.51M | $38.96M | $35.19M | $26.71M | $17.99M | $8.12M | 30.2% | +22.6% |
| DNA synthesis and protein solutions | $23.45M | $20.33M | $23.17M | $24.17M | $6.99M | $2.38M | – | – | – | 6.2% | +15.4% |
| Oligo pools | $20.23M | $16.91M | $14.49M | $12.42M | $8.04M | $4.55M | $4.59M | $3.00M | $2.06M | 5.4% | +19.7% |
| DNA libraries | $11.18M | $13.93M | $10.20M | $6.15M | $5.68M | $3.97M | $2.04M | $1.77M | – | 3.0% | -19.7% |
| DNA Libraries [Member] | – | – | – | – | – | – | $2.04M | $1.77M | $517.00K | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Americas | $225.58M | $193.88M | $151.26M | $122.47M | $77.91M | $59.16M | $36.93M | $207.00K | – | 59.9% | +16.3% |
| EMEA | $124.24M | $92.57M | $71.39M | $62.08M | $44.12M | $25.82M | $14.69M | $6.56M | $2.02M | 33.0% | +34.2% |
| APAC | $26.75M | $26.52M | $22.46M | $19.01M | $10.30M | $5.12M | $2.76M | $1.00M | $274.00K | 7.1% | +0.9% |
| United States | – | – | – | – | – | $58.08M | $35.94M | $17.66M | $8.24M | – | – |
| North America [Member] | – | – | – | – | – | – | $996.00K | $207.00K | $227.00K | – | – |
From the segment and revenue-disaggregation notes of Twist Bioscience's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.